Agenda


Opening Plenary


13:00
KEYNOTE ADDRESS:
COVID-19 Treatments and Vaccines – Ushering in a New Era for Regulation, Collaboration, and Drug Accessibility

13:30
PHARMA LEADERS’ THINK TANK:
Redefining Pharma’s Role in the Global Healthcare Reform Agenda

  • COVID-19 vaccines candidate development
  • Regulations on pandemic drugs approval and accelerated clinical trials under diverse regimes
  • Future of pricing and affordability for Novel Drugs
  • Why technology should be the key component to surviving COVID-19?
  • AI and its immense potential in use of pandemic treatments and early detection

Panellists:
Dr. Sucharita Das, Head of Regulatory Affairs and Quality Assurance APAC, Pfizer, Singapore
Edsel Pereira
, Group Vice President – Information Technology, Glenmark Pharmaceuticals, India
Alexander Zach
, Senior Vice President, Global Head of Market Access and Policy, Biocon, India*
Dr. Keith Carpenter
, A*STAR Senior Fellow, Pharma Innovation Programme Singapore (PIPs), Singapore*

14:10
Online Networking and Stretch Break

3rd Digital Pharma


COVID-19 & A Digital Reset


15:00
Innovation Imperatives from COVID-19:
Converting the Need to Innovate and Aspiration into a Tangible Reality

  • How COVID-19 made us rethink our innovations and resilient digital strategies?
  • Data-driven internal and external customer outreach – where do we stand?
  • How can companies make the first step into an innovative culture?
  • Is there real tangible value to being innovative?

Geoff Wade, Chief Information Officer, AstraZeneca Asia, Singapore

15:30
COVID-19 Case Study: The Promise and Challenge of Big Data for Pharma

  • Novel coronavirus (COVID-19) – Industry’s R&D efforts
  • Current applications of data science in novel drug R&D
  • Bottlenecks with the use of data in drug development
  • Why does pharma need a “data science mindset”?
  • How far are we from completely replacing clinical trial evidence with real-world data sources?

Dr. Takashi Moriya, Director, Data Sciences, Research & Development Division, Janssen Pharmaceutical K.K. (Japan)

16:00
How is Artificial Intelligence Changing Drug Discovery and Advanced R&D?

  • The digital response to COVID-19 and new investment drivers
  • Key AI areas and projects in healthcare and pharma
  • AI in Drug Discovery – Accelerating the development of new treatments
  • International collaboration as key component of the government’s AI innovation development strategy

George Tseng, CEO, All Vista Healthcare Sub-center, Ministry of Science and Technology (MOST) Joint Research Center for AI Technology and All Vista Healthcare, Taiwan

16:30
Tech Use in Trials, in the Case of COVID-19

  • Overview of digital tech opportunities for clinical trials
  • Recruitment for clinical and market research using digital health platforms
  • Redesigning and scaling up trials with IoT
  • Supply chain management with blockchain tech
  • Automated analyses and insights from big data with AI
  • Case Study: AskDr, a local digital solution initiated in response to COVID-19
  • Avenues for investments and co-development in digital health

Dr. Dinesh Visva Gunsekeran, Senior Lecturer (Medical Innovation), National University of Singapore, Clinical Researcher (Artificial Intelligence in Ophthalmology, Singapore General Hospital, Singapore

17:00
Pharma Supply Chain and How Next-Gen Digital Applications will reshape SCM post COVID 19

  • Applications of analytics in Glenmark’s pharma supply chain outreach
  • Monitoring drug, and ingredients supply chain for impact of COVID-19 pandemic
  • COVID-19: Managing supply chain risk and disruption
  • Addressing track and trace compliance requirements: One of India pharma industry’s most critical challenges globally

Edsel Pereira, Group Vice President - Information Technology, Glenmark Pharmaceuticals, India

17:30
End of Virtual Conference Day 1

13th Pharma Regulatory Affairs


Regulatory Priorities Post COVID-19


15:00
Assessing Regulatory Requirements and Expectations In Japan During COVID-19

  • Key regulatory aspects for new drugs development in japan
  • Approval timelines and accelerated review system
  • New regulation on shorten the clinical trials notification (CTN) of Covid-19 candidate product
  • New developments and outlook for Cell & Gene Therapy products

Yuko Kikuchi, Senor Director Asia Regulatory Affairs, Eisai, Japan

15:30
Regulatory Transformation and the Drug Approval Process in Vietnam

  • Major issues facing regulatory transformation in Vietnam
  • Ongoing regulatory reform
  • GAMP and compliance update

Ewelina Markuszewska, Quality Control Expert, DaviPharm (Adamed Group), Vietnam

16:00
Regulatory Leaders’ Dialogue:
Managing Expectations from Regional FDAs During and After COVID-19

  • Renewals and ‘sunset clause’
  • Potential COVID products and choosing the right paths with FDAs
  • COVID -19 impacts on trials conducts
  • Understanding and working well with FDAs’ prioritisation rationale
  • Revisiting regulatory strategies during and thereafter pandemic
  • Challenges to opportunities – Timelines management for documentation, submission and approvals
  • Regulatory Affairs expert views on successful pathways during pandemic whilst meeting regulatory goals

Panellists
Yuko Kikuchi, Senor Director Asia Regulatory Affairs, Eisai, Japan
Santosh Kumar Jha
, Head, Head, Asia Pacific Region Medical & Regulatory Affairs, Takeda, Singapore
Ewelina Markuszewska
, Quality Control Expert, DaviPharm (Adamed Group), Vietnam
Sophia Huang
, Regional Group Head, Regulatory Submission Management, Bayer, China


COVID-19: REGULATORY FEXIBILTY AND DEVELOPMENTS


16:40
Assessing the Impacts of COVID-19 Against Pharma Competition Law

  • Drug development, pricing and access against COVID-19

Dr. Sucharita Das, Head of Regulatory Affairs and Quality Assurance APAC, Pfizer Pharmaceuticals, Japan, China, Singapore

17:10
Regulatory Affairs Priority Setting:
Speed and Flexibility for Drug Development During and After COVID-19

  • Regulatory priorities for department and wider company
  • Better and efficient engagement with Authorities for speed to market authorisation plans – Benchmarking globally
  • Working well with anticipated regulatory changes post COVID-19
  • Regulatory update of drug development on Covid-19

18:00
End of Virtual Conference Day 1

4th Market Access and Pricing


COVID-19 Impacts on Pricing and Access


15:00
COVID-19 Response Dialogue: Accelerating Speed to Market, Drug Accessibility and Affordability

  • Assessing regulator’s priority, managing delays and disruption on appraisals
  • Not so new normal: Impediments to commercialising drugs at the same speed and scale
  • Donation and pricing commitments from pharma manufacturers
  • Developments in Government pricing and reimbursement
  • How will pharma price the affordable therapeutics against COVID-19?

Moderator:
Alexander Zach, Senior Vice President, Global Head of Market Access and Policy, Biocon, India

Panellists:
Yelitte Ho, Australian Pharmacist and Pharmaceutical Policy Advisor, Australia
Sayantani Dasgupta
, Associate Director, Customer Engagement Strategy & Commercial Excellence, Merck, Japan
Viviendouf Koh
, Regional Marketing Manager, South and East Asia, Lundbeck, Singapore
Jek Fong
, Director, Market Access and Personalised Healthcare, Roche, Singapore
More panellists to be confirmed

15:40
Managing the Effects of COVID-19 on Drug Access

  • Propagating international access for drugs
  • Improving access for high cost drugs – will it be the case for coronavirus treatments? -Creating innovative value
  • Overcoming access difficulties in regions

Alexander Zach, Senior Vice President, Global Head of Market Access and Policy, Biocon, India

16:10
Case study of Greater Access – Merck and The Jenner Institute COVID-19 Vaccine Manufacturing

  • Redefine, transform and innovate pharma business strategy for greater access
  • Adjusting commercial models- patient-physician relationships
  • Catering to high population markets

Sayantani Dasgupta, Associate Director, Customer Engagement Strategy & Commercial Excellence, Merck, Japan

16:40
Gilead Science Case Study:
COVID-19: Ramping up Remdesivir Production for Affordable Access and Pricing

17:10
Roche’s Case Study: Approaches for Urgency to Market in the Fight Against COVID-19

  • Beyond the antibody test
  • Case study- drug development and access acceleration

Jek Fong, Director, Market Access and Personalised Healthcare, Roche, Singapore

End of Virtual Conference Day 1

Accelerating Clinical Trials

Programme to be announced

3rd Digital Pharma


Health Tech Investments & Partnerships


13:00
SGINNOVATE KEYNOTE ADDRESS:
Understanding Collaboration in Unprecedented Times: The Corporate Perspective

  • Why are VCs and corporate ventures courting digital health start-ups?
  • COVID-19: Start-ups excelling in a time of crisis
  • What do start-ups want from their corporate accelerator partners, and vice-versa?
  • When does a collaboration make sense for each of the parties involved?
  • Which questions need to be solved to collaborate successfully?

Hsien-Hui Tong, Head, Venture Investing, SGInnovate, Singapore

13:30
PHARMA INNOVATION PROGRAMME SINGAPORE (PIPS) CASE STUDY:
Accelerated Digital Innovation During COVID-19 and Beyond

  • PIPs’ views on COVID-19 – Investment potential, focused tech areas, and who is being engaged
  • Observed market trends and how is PIPs working with the private sector to leverage on and adapt to these trends
  • Some issues facing manufacturing and supply chains in digitization
  • COVID-19 and its impact on pharma supply chain and manufacturing
  • Rapid process development and introduction

Dr. Keith Carpenter, A*STAR Senior Fellow, Pharma Innovation Programme Singapore (PIPs), Singapore

14:00
AI and Big Data Developments in Pharma

  • Coronavirus impact – Global AI R&D spend by pharmaceuticals
  • AI powered drug discovery and manufacturing
  • Making sense of data – An urban legend in pharma industry?
  • What can and can’t do by AI – To what extent can AI make critical decisions for us?
  • Critical steps to establishing an effective AI strategy
  • Rethinking business models in the age of AI
  • Collaborative innovation: Finding right partners to leverage on new tech in pharma

Panelists:
Dr. Dinesh Visva Gunsekeran, Senior Lecturer (Medical Innovation), National University of Singapore, Clinical Researcher (Artificial Intelligence in Ophthalmology, Singapore General Hospital, Singapore
Kirtan Verma
, Global Channel Excellence Lead, GSK, Singapore

15:00
Online Networking and Stretch Break

15:30
PHARMA TECH START-UP SHOWCASE:
4 startups at the forefront of drug discovery and treatment R&D have been selected to pitch to a targeted audience of pharma manufacturers, biotechs, tech providers, VCs and investors.

15:30
Mesh Bio: Transforming Chronic Disease Management through Predictive Analytics

Dr. Andrew Wu, CEO and Co-Founder, Mesh Bio, Singapore

15:45
Eko.ai.: Automating the Fight against Heart Disease

Senior Representative from Eko.ai., Singapore

16:00
Medo.ai: AI-Augmented 3D Ultrasound platform at your fingertip

Dornoosh Zonoobi, Co-Founder and CEO, Medo.ai, Canada

16:15
Qritive: Accelerate R&D: AI-powered histopathology

Dr. Aneesh Sathe, CEO and Co-Founder, Qritive, Singapore

16:30
End of Virtual Conference Day 2

13th Pharma Regulatory Affairs


COVID-19: Regulatory Flexibility And Developments


13:00
Regulatory Perspective:
Expediting Drug Approval During COVID-19 Outbreak

  • Takeda pharma initiatives on developing Plasma-derived therapy to treat COVID-19 patients
  • Therapeutic development procedures
  • Regulatory view on expediting drug approval during Covid-19 outbreak
  • Latest progress on the drug development

Santosh Kumar Jha, Head, Asia Pacific Region Medical & Regulatory Affairs, Takeda, Singapore

13:30
Life-Cycle Approach to Quality and Safety of Pharmaceutical Products – Case Study During COVID-19 Crisis

  • Current trends in global lifecycle management and situation in the region
  • Challenges in the development and manufacture of complex drug delivery devices
  • Strategy to navigate the complexities of CMC process

Dr. Nirmal Kumar, Head-QA, Novugen Pharma (Malaysia) Sdn Bhd, Malaysia

14:00
Regional Progress and Update on Multi Regional Clinical Trials (MRCTs)

  • MRCTs and COVID trials updates
  • Roadmap to promote MRCTs in Asia
  • Key consideration for effective regulatory decision-making using MRCTs

Lilian Chow, Vice President of Clinical Operations and Regulatory Affairs, Cerecin, Singapore


Pricing, Products and Regulations           


14:30
The Update on the New Price Control Implementation in the Philippines

  • Are price controls the solution to expensive drugs?
  • The update on the new retail price regulation
  • Long-term investment impact in the Philippines’s pharma industry
  • Strategy to manage the cost containment

Catherine Clemente, Associate Lead, Drug Regulatory Affairs & Pharmacovigilance, Sandoz, Philippines

15:00
Online Networking and Stretch Break

15:30
Generics, Biosimilars, Combination Therapies and Biologics

  • Global development update for biologic products
  • Overview of the registration procedure and approval process for both generics and biosimilars in Asia
  • Pricing mechanisms
  • Commercialisation risk during COVID-19 pandemic

Pakhi Rusia, Director, Global Regulatory Affairs, GlaxoSmithKline Consumer Healthcare, Singapore

16:00
Asia OTC Regulatory Strategy
Development

  • OTC regulatory framework in Asia Pacific
  • ASEAN pharmaceutical harmonization implementation and its implication to OTC development
  • Case study

Srilatha Sreepathy, Associate Director, Regulatory & Pipeline Strategy Asia, Procter & Gamble, Singapore

16:30
Knowledge Session:
Regulatory Submissions Guidance:

  • Working with Various FDAs During COVID-19
  • The Case Study of: United States, EU, China, Australia, New Zealand and ASEAN countries

Speaking opportunity please contact dewi.febianti@informa.com

17:00
End of Day 2 Virtual Conference
                         

4th Market Access and Pricing


Agile Market Access


13:00
Agile and Increased Capability for Market Access for Non-COVID Drugs

  • Working in the era of changed business models, price negotiation and FDA’s shifting priorities
  • Strengthening regional health systems with partnerships
  • Regional case studies- challenges and opportunities
  • Strategies to introduce biosimilars into Asia

Mark Tennyson, JAPAC Regional Head, Value, Access and Policy, Amgen, Hong Kong

14:00
Fair Pricing and Drug Affordability Whilst Satisfying Governments Healthcare Policy  

  • ASEAN and Asia market analysis
  • Working with different reimbursement regimes – Aiming for a Win-Win situation
  • Managing drug development costs, investments and ROIs
  • Improving drug access and copayment- What is the right balance?
  • Developed vs emerging market landscapes: What are the key considerations for growth

Moderator:
Jun Feng
, Market Access Associate Director, Oncology, JAPAC, AbbVie, Singapore  

Panellists:
Mark Tennyson
, JAPAC Regional Head, Value, Access and Policy, Amgen, Hong Kong
Nathan K
, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia
Judy Deng
, Head of Market Access, Oncology, Novartis, China
More panellists to be confirmed

14:40
China’s Drug Landscape – The Medical Insurance Reform of Tripartite System and Implications for Market Access

  • Access for innovative therapies in China
  • What are CFDA’s priorities?
  • Practical considerations and negotiations for placement onto the list of National Reimbursement Drug List (NRDL)
  • Proving value for innovative therapies
  • China case study: Managing access for cancer drugs post COVID-19 outbreak

Judy Deng, Head of Market Access, Oncology, Novartis, China

15:00
Online Networking and Stretch Break

16:00
Oncology and COVID-19: Setting the Priority Right 

  • Building access to cancer care in emerging markets
  • India’s case study: Rat race between oncology drugs and COVID-19
  • Building portfolio and connecting with customers
  • Using digital tools and access strategies

Anupama Rao Singh, Director, Oncology and Hospital CoE, Global Generics, Emerging Markets, Dr Reddys, India

16:30
Affordability for Rare Diseases- Challenges and Opportunities

For speaking enquiry, please contact Yvonne.Leong@informa.com

17:00
End of Day 2 Virtual Conference                                                                                                                                                                              

Accelerating Clinical Trials

Programme to be announced

3rd Digital Pharma


Digitalising Consumer Engagement


13:00
How is Digital Tech Empowering the Self-Care Movement? 

  • How OTC market helps manage a pandemic?
  • Evolution of consumer-facing applications in the OTC market: From hospitals to smartphones, to home interconnections
  • Some use cases of wearables and mHealth applications in the OTC market
  • Digital strategies for improving OTC marketing success

Angela Brady, Director of Innovation Research, APAC R&D, GSK, Singapore          

13:30
Data-Driven Process Excellence – RPA in Pharma

  • Improving pharma workflows with better Process Management during pandemic crisis
  • Why process excellence matters to the pharma industry
  • Opportunities of business process management as a driver of innovation
  • Best practices for implementing process improvements
  • Some key process implementation pitfalls

Azuhar Mohammed, Head of Global Solution Center – Expertise & Innovation, Sanofi, Singapore

14:00
Driving Sales Force Effectiveness through new Consumer Engagement practices 

  • Drivers for business intelligence solutions in the pharma industry
  • Data challenges faced by pharma companies
  • Sales force effectiveness (SFE) best practices and latest trends
  • How to optimise pharma sales forces in times ripe for pandemics

Sharika Menon, Customer Engagement & Commercial Education Lead, Johnson & Johnson, Singapore   

14:30
Transforming The Way We Engage HCPs

  • Email Marketing, does it really work?
  • Importance of content marketing for pharma brands to deal with “Dr. Google”
  • Going beyond informative content
  • Augmenting Pharma Marketing via Commercial Activity
  • Rapid Adjustment of Customer Experience Strategy in Response to COVID-19

Desmond Lim, Digital Content & Capability Lead, Pfizer, Singapore

15:00
Online Networking and Stretch Break


Digital Transformation In Emerging Markets


15:30
Case Study: Development of Digital Distribution Channels in Indonesia

  • Trends in the retailing and distribution landscape
  • How did pharma distributors adjust to the COVID-19 pandemic?
  • Reengineering pharmaceutical networks for the digital era
  • E-commerce UI/UX design: Principles and Strategies

Agustina Siahaan, Head of IT, SOHO Global Health, Indonesia

15:50
Establishing and Accelerating OTC Brand Growth in E-Commerce 

  • Overview of e-commerce trends in the consumer healthcare sector
  • Current state of e-commerce infrastructure development and baseline establishment
  • Growth acceleration plan to win in consumer healthcare

Hesnuaril Marlindayani, Head of E-Commerce & Digital, Consumer Health Indonesia, PT Bayer Indonesia

16:10
Case Study: Orchestrated Customer Engagement in Vietnam: From CRM to the CLM 

  • State of digital tools for customer engagement in Vietnam’s pharma market
  • Improving physician and patient engagement through Digital Journey Customer Mapping
  • How to develop an effective data flow management system and enhance targeted contents effectively for HCP activities

Danh Nguyen, Country Managing Director, Besins Healthcare, Vietnam

16:40
DIVERSITY & INCLUSION IN PHARMA:
Cultivating the Next-Gen of Women Leaders in Pharma

  • Why does gender equality matter on the board?
  • Key challenges facing women leaders in Pharma
  • Management efforts to address some of these challenges, and remaining gaps
  • Reflections on the journey to the top
  • Breaking the glass ceiling: Lessons learnt along the way, and advice to my younger self
  • Management efforts to address some of these challenges, and remaining gaps

Panelists:
Anupama Rao Singh
, Director, Oncology and Hospital CoE, Global Generics, Emerging Markets, Dr. Reddy’s Laboratories, India
Angela Brady
, Director of Innovation Research, APAC R&D, GSK, Singapore
More panelists to be confirmed.                                                                                                                                              

17:00
End of Day 3 Virtual Conference

13th Pharma Regulatory Affairs


Digitally Transformed Reg Affairs


13:00
Digital Transformation and Regulatory Needs

  • Regulatory developments to support the digitalization of pharma
  • Challenges, opportunity, and benefit
  • Pharma digitalization implementation in Thailand

Phusit Prakongsai, Acting Senior Advisor on Health Promotion, Office of Permanent Secretary, Ministry of Public Health Thailand, Thailand

13:30
International eCTD Implementation and Examining the Common Pitfalls

  • Timelines, scope and pros and cons in Asia
  • Assessing the status of eCTD v4.0
  • Successful case study of eCTD implementation
  • An update on eSubmission in China

Sophia Huang, Regional Group Head, Regulatory Submission Management, Bayer, China

14:00
E-Retail Regulatory Updates:
E-commerce for Self-Care in ASEAN

  • Relationship between Self-care and e-Commerce
  • E-Commerce model used in consumer self-care environment
  • Learnings from ASEAN countries

Woei Lee Chen, Head of Regulatory Affairs, Reckitt Benckiser, Singapore

14:30
Knowledge Session:
eCTD in APAC and Technology Transformation

  • Addressing digitally transformed regulatory affairs

Speaking opportunity please contact dewi.febianti@outlook.com

15:00
Online Networking and Stretch Break


Pharmacovigilance


15:30
Pharmacovigilance System and Its Implementation in Indonesia

  • Examining Indonesia’s regulatory landscape
  • What are the regulatory pathways and strategic considerations for successful clinical trial and marketing applications?
  • Regulatory risk management on pharmacovigilance – pre and post marketing

Diani Savitri, Regulatory & Pharmacovigilance Director, Soho Global Health, Indonesia

16:00
Comparisons of CMC Variations in the Region & Managing Complications

  • Requirements and challenges in design and change in manufacturing process and product specifications
  • Stability studies
  • Similarities and differences with post approval changes in ASEAN/US/EU
  • How these CMC processes and issues relate to the product’s regulatory strategy

Aziza Ahmed, Director, APAC CMC Regulatory Affairs, MSD International GMBH, Singapore

17:00
End of Day 3 Virtual Conference                                                                                                                                                                              

4th Market Access and Pricing


Payer and Reimbursement


13:00
Case Study:
Lundbeck’s Value Creation Strategies in Asia 

  • Working with payers, patients and reimbursement bodies for creating customer-focused values
  • Value creation for disease area of psychiatry
  • Lowering stigma for treatments in neurology and psychiatry

 Viviendouf Koh, Regional Marketing Manager, South and East Asia, Lundbeck, Singapore

13:30
Pharma Partnerships for Affordable Healthcare 

For speaking enquiry, please contact Yvonne.Leong@informa.com

14:00
Australia Case Study:
COVID-19 Government, Reimbursement & Regulatory Updates 

  • COVID-19 in Australia
  • Universal access to healthcare in Australia and the Pharmaceutical Benefits Scheme (PBS)
  • Universal Subsidy Scheme for Medicines
  • How does a drug get listed on the PBS (registration process, pricing, listing consideration)?
  • Key factors influencing decision making by the independent Pharmaceutical Benefits Advisory Committee
  • Patent and data protection of pharmaceuticals in Australia

Yelitte Ho, Australian Pharmacist and Pharmaceutical Policy Advisor, Australia   


Optimising RWE and HTA         


 14:30
Demonstrating Value and Data Gathering for RWE in Asia

  • Understand how RWE is different from randomized control trials (RCTs)
  • How do Regulatory bodies consider the use of RWE for decision making?
  • Challenges to collect RWE; how to access and when to use do we have that ready in Asia
  • Successful regional case studies

Kim Soyoung, Director HEOR, Medical Affairs, Asia & Oceania, Astellas Pharma, Singapore

15:00
Online Networking and Stretch Break

15:30
Use of Real-World Evidence in the Drug Registration Process 

  • What’s real World Data, Real world Evidence?
  • How is Real World Evidence generated?
  • Overview of Regulations (US FDA, EMA, China NMPA)

Gaelle Richer, Director Global Regulatory Affairs, GSK, Singapore

16:00
HTA for Growing Economies

  • Challenges and Opportunities of using HTA
  • Key areas of focus for emerging markets
  • Maximising the returns of HTA on proving drug value

Nathan K, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia

17:00
End of Day 3 Virtual Conference                                                                                                                                                                              

Accelerating Clinical Trials

Programme to be announced